Navigation Links
AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Date:1/28/2010

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term future looks strong.

"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."

The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email

SOURCE AstraZeneca Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
2. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
3. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
4. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
7. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
8. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
9. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
10. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... AURORA, Colo. and BANGALORE, India ... a global genomic profiling company that uses next generation ... appointment of Scott A. Storrer as chief ... and CEO, he will be responsible for all strategy, ... Vijay Chandru , who has served as Strand,s chairman ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest ... the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge ... of US$15,000 and a period of expert mentorship from a senior industry figure drawn ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... Genetics, Inc. (OTCQB: ILIU) announced today that it will ... at 4:30 p.m. (EST) to discuss the Company,s third quarter ... (domestic) or 631-291-4550 (international). The live Webcast and replay access ... of Interleukin Genetics, Inc.,s Website at http://www.ilgenetics.com . ...
... SAN DIEGO, Nov. 3, 2011 Optimer Pharmaceuticals, Inc. ... financial results for the quarter ended September 30, 2011. ... Optimer reported total revenues for the third quarter of ... quarter in 2010. This includes net product sales of ...
... Nov. 3, 2011 Bacterin International Holdings, Inc. ... in the development of revolutionary bone graft material and ... founding sponsor of the Resources for Medical Education and ... educational grant. The goal of the Osteobiologics ...
Cached Biology Technology:Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results 2Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Bacterin Becomes Premier Founding Sponsor of RMEC's New Osteobiologics Registry 2Bacterin Becomes Premier Founding Sponsor of RMEC's New Osteobiologics Registry 3
(Date:6/18/2015)... NEW YORK , June 18, 2015 ... in US$ Million by the following Product Segments, which ... Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and ... for the US, Canada , ... Asia-Pacific , Latin America ...
(Date:6/17/2015)... , June 17, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Xiaomi, one of the ... ® ClearPad ® family of capacitive ... integrated circuits (DDICs) for its latest smartphones, the ... ClearPad for full in-cell display solutions and DDICs ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... on the early cell mutations that enable a cancer to grow ... to stop it. Scientists were able to use a statistical approach ... these abnormalities form to analyze the pattern of DNA changes in ... published in the July edition of Cancer Discovery , are ...
... to spew ash that is still disrupting travel as ... new animation of satellite imagery just released from the ... volcano. Satellite data from the Geostationary Operational Environmental ... have been providing images of the volcanic plume since ...
... Carolina State University researchers has discovered more about how a ... adults does its job. Their findings could pave the way ... areas of the brain do not generate new brain cells, ... olfactory bulb, the brain,s scent processor, which continually produces new ...
Cached Biology News:Scientists develop method to determine order of mutations that lead to cancer 2Genetic 'conductor' involved with new brain cell production in adults 2
Recombinant Mouse LIGHT/TNFSF14...
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Biology Products: